原代培养卵巢癌细胞体外药敏试验与临床应用评价  

Drug Sensitivity and Evaluation of Clinical Use of Primarily Cultured Ovarian Cancer Cells

作　　者：曹丽芝[1] 陈金燕[1] 曾东向[1] 

机构地区：[1]湖南省肿瘤医院临床药学室,长沙410013

出　　处：《医药导报》2009年第7期940-942,共3页Herald of Medicine

摘　　要：目的研究MTT法测定卵巢癌对化疗药物体外敏感性,评价其对卵巢癌化疗药物选择的临床价值。方法将46例新鲜卵巢癌标本进行体外原代细胞培养,并对11种常用化疗药物及联合用药的敏感性进行测定,并与临床实际用药进行3a的跟踪比较,评价其疗效。结果肿瘤细胞体外药敏存在着明显的个体差异,而其平均抑制率结果与临床用药情况的总预测准确率为89.1%。结论肿瘤细胞体外药敏试验结果可以为临床个体化治疗提供参考。Objective To study the sensitivity of ovarian cancer cells to chemotherapeutic drugs in vitro by MTT assay, and evaluate the clinical value of selecting drugs for ovarian cancer chemotherapy. Methods The fresh cells from 46 human ovarian cancer samples were prepared and primarily cultured in vitro, and used for determining drug sensitivity of 11 kinds of common chemotherapeutic drugs and the combination of them, which was compared with 3 years follow - up evaluation of their clinical efficacy. Results There is a clear individual difference for drug sensitivity of ovarian cells in vitro, and the average suppression of drug action and the total forecast accuracy was 89.1%. Conclusion The drug sensitivity test of tumor cells in vitro could provide some references for individual chemotherapy.

关 键 词：MTT法 原代培养 肿瘤药敏 临床应用 

分 类 号：R979.1[医药卫生—药品]